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Abstract: 
Equine Degenerative Myeloencephalopathy (EDM), a neurological disease of young horses, 
causes progressive development of symmetric ataxia predominantly in the pelvic limbs. EDM 
is likely inherited and with no known treatment affected horses frequently need euthanasia. 
Alpha-tocopherol deficiency during early life appears to contribute to the phenotype. This 
study sought to identify any genetic variants correlated with EDM in Caspian foals. Two 
half-sibling EDM diagnosed cases were genotyped at 52,063 loci and evaluated by the 
Autozygosity by Difference statistic. Additional horses not affected by EDM were used for 
genetic comparison to identify regions unique to the case phenotype. The associated region 
on chromosome 3 contains only one gene encoding adhesion G protein-coupled receptor L3 
(ADGRL3). ADGRL3 is a member of the latrophilin subfamily of G-protein coupled receptors 
and may contribute to Attention Deficit/Hyperactivity Disorder in humans and hyperactive 
motor function in mice and zebrafish. Analysis of the predicted coding regions for Equine 
ADGRL3 in affected horses revealed a non-synonymous SNP at Chr3:71,917,591 bp. Caspian 
and Caspian cross relatives (n=81) of the two initial cases, as well as unrelated horses from 
similar breeds (n=130, including Arabians, American Miniatures, and Shetlands) possessed 
this allele at 5% frequency, with no homozygotes observed within the non-Caspian breeds. 
This study suggests that a polymorphism in ADGRL3 could contribute to a genetic 
predisposition to Caspian Horse EDM. 
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1. Introduction  
Equine Degenerative Myeloencephalopathy (EDM), a more severe variant of equine 
neuroaxonal dystrophy (eNAD), is a progressive neurological disease found in young horses. 
Clinical signs generally develop within the first year of life and most commonly present as 
symmetric ataxia and weakness, affecting either the hind limbs only or all four limbs [1, 2]. 
Diagnosis is confirmed at necropsy by observation of axonal degeneration in specific neurons 
within the caudal medulla oblongata and cervicothoracic spinal cord [1]. EDM has been 
previously reported in Arabians, Appaloosas, Lusitanos, and Welsh Ponies, among various 
other breeds, including mixed breeds [3-7]. Evidence for a genetic influence for the disease is 
provided by breeding trials and risk factor analysis, however different inheritance patterns 
have been observed across different breeds [5, 7-11].  
 
Vitamin E, specifically alpha-tocopherol, deficiency is associated with the incidence and 
severity of EDM [12]. Alpha-tocopherol supplementation reduces the severity and incidence 
in genetically predisposed foals [8, 11]. However, all reported cases may not be deficient in 
alpha-tocopherol at the time of diagnosis [9, 11]. It was recently demonstrated that the risk 
period where alpha-tocopherol deficiency may affect the phenotype is in the first 6 months of 
life [13].   
 
The Caspian breed, originally developed in Northern Iran, is a rare breed that comprises 
approximately 1,600 horses worldwide. Close to extinction in the middle 20th century, an 
American horse breeder rediscovered the Caspian horse and promoted the introduction of this 
small breed into many countries. Caspian horses have undergone several population 
bottlenecks and founding events, resulting in decreased heterozygosity [14, 15]. This lack of 
heterozygosity increases the chance that deleterious recessive alleles will be observed in the 
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current population and provides a unique opportunity for genetic mapping efforts. Without 
monitoring for possible genetic faults, the future of the Caspian is uncertain, especially if a 
deleterious or sub-lethal recessive trait is carried within the population.  
 
Two EDM cases submitted for genetic evaluation were genotyped on the equine 54K SNP 
chip and analyzed by a novel method, Autozygosity by Difference (ABD), to identify 
possible regions contributing to the disease. Through fine-mapping, a candidate variant was 
found in association with the disease and may be contributing to genetic predisposition, in 
conjunction with environmental factors, for development of EDM within the Caspian breed.  
 
2. Materials & Methods  
2.1 Proband Cases  
Two half-sib yearling foals, a Caspian and Caspian cross, sharing a sire, were examined 
because of progressive and symmetrical ataxia of several months duration. They were scored 
using a modified grading scale for ataxia and neurologic deficits from 0-5, with 0 being 
normal and 5 being recumbent [16]. Both foals scored a 4 in the pelvic limbs and 1-2 in the 
thoracic limbs. The foals were from the same farm and it was reported that some previous 
weanling and yearlings from this farm had been euthanized because of similar clinical signs. 
Necropsy found bilateral symmetric demyelination and axonal loss around the 
spinocerebellar tracts in both cases, confirming the diagnosis as EDM. One case had low 
serum alpha-tocopherol concentration of 161 ug/dL (normal range 200-400 ug/dL). Testing 
was performed after the yearling had access to some pasture. It was assumed the other case 
was deficient because of a history of poor quality hay, limited pasture, and no additional 
alpha-tocopherol supplementation in the herd.  
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2.2 Horses  
All horses had hair or tissue samples taken following protocols approved by the Cornell 
University Institutional Animal Care and Use Committee. All horse owners signed a consent 
form prior to their horses being sampled. Eighty-one Caspian and Caspian-cross relatives, as 
well as one Shetland (dam of a case) were submitted voluntarily by owners. The Caspian 
horses available shared common ancestry within 3-4 generations and we accounted for this 
using family-based statistical tests. An additional unrelated 130 horses were utilized to 
establish the allele frequency (13 Shetlands, 48 Arabians, and 69 Miniatures). These 
additional horses were selected to ensure each one was not related to another within one 
generation. 
 
2.3 DNA extraction  
Genomic DNA from the affected foals was obtained from tissue samples using a Qiagen 
Puregene Kit following the manufacturer’s recommended protocol. Genomic DNA from all 
other horses was extracted from hair bulbs using a modified Qiagen Puregene Protocol as 
previously published [17]. 
 
2.4 Autozygosity by Difference method  
Autozygosity by Difference (ABD) identifies homozygous regions of the genome using 
genome-wide SNP data [18]. The two cases and 90 controls from other studies [19, 20] were 
genotyped on the Equine 54K SNP Chip. SNPs located on the sex chromosomes were 
excluded leaving 52,063 SNPs for analysis. ABD identifies the most common homozygous 
genotype (CHG) in the cases at each individual SNP. A run of homozygosity (ROH) is 
considered to be two or more adjacent CHG SNPs. Each ROH is scored on all chromosomes 
for each case and control. Each SNP in a ROH obtains a score based on the number of SNPs 
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in that ROH. Each SNP is analyzed by comparing the means for cases and controls. The 
mutation should be in the region with the highest score difference between cases and 
controls. Significance of the identified scores is calculated by permutation. This is achieved 
by repeatedly rescoring the dataset with phenotypes randomly allocated to subjects and 
including the original cases and controls in the permutations 1,000 times (N). The probability 
of each score is the proportion of occasions when that score, and all those greater than it, was 
achieved, out of N times the number of SNP tested. 
 
2.5 Adhesion G Protein–Coupled Receptor L3 Sequencing  
Adhesion G Protein–Coupled Receptor L3 Sequencing (ADGRL3) exons were inferred based 
on homology with the human, mouse, rat, and bovine genes using the UCSC Genome 
Browser. Primers covering the orthologous exons, 5’ end, and 3’ end were designed based on 
the equCab2.0 assembly from the UCSC Genome Browser using Primer3 software [21] and 
purchased through Integrated DNA Technologies (Coralville, Iowa) (Supplemental Table 1).  
 
Polymerase chain reaction (PCR) products from all primer sets from both cases and a control 
were sent to Cornell University Life Science Core Laboratory Center for Sequencing using 
Applied Biosystems Automated 3730xl DNA Analyzers and run according to manufacturer’s 
recommendations.  
 
Sequences were compared to detect variation using CodonCode Aligner (CodonCode Corp, 
Dedham, MA). These were also compared to the reference genome utilizing the UCSC 
Genome Browser [22]. DNA changes that resulted in amino acid changes were tested for a 
predicted functional effect using PROVEAN [23].  
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2.6 Statistical Analysis of Association 
Genotypic and allelic frequencies were used to determine statistical significance through 
association using the recessive model for the entire dataset (n=212) and a family based TDT 
for the Caspian individuals (n=81) using PLINK 1.9 [24]. Hardy-Weinberg Equilibrium was 
tested within breed using an exact test in R [25, 26].  
 
3. Results  
3.1 Autozygosity by Difference  
Through the ABD method, a run of homozygosity was found on Chromosome 3 from 
71,381,589-73,566,775 bp (Figure 1). This region has a difference score of 376.47, which is 
significantly higher (p<0.001) than the rest of the genome with an average score of 7.11. 
Only one gene is located within this region, adhesion G protein-coupled receptor L3 
(ADGRL3). The ABD score difference pattern suggests an autosomal recessive pattern of 
inheritance.  
 
3.2 ADGRL3 Sequencing  
Four SNPs were identified via Sanger Sequencing; two in exons, one in an intron, and one in 
the 3’ UTR (Supplemental Table 2). The SNP at chr3:71,770,084 was prioritized for further 
evaluation because it is a non-synonymous change and followed the recessive inheritance 
pattern indicated by the ABD mapping results. This SNP causes an amino acid change from 
asparagine to serine and resulted in a PROVEAN score of -0.962, indicating a slightly 
deleterious mutation. Two predicted ADGRL3 coding sequences, an affected and an 
unaffected, were submitted to GenBank under the following accession numbers: KJ526819 
and KJ526820. 
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3.3 Allele Frequency in source herd & other breeds  
Genotypic and allelic frequencies are seen in Table 1. There were no homozygotes found in 
the other breeds tested. Association with the disease using a family based TDT for the 
Caspian horse cohort (n=81) was also significant (p=0.0455). Testing for an allelic 
association using the recessive model (n=212) revealed a significant association (p<0.001). 
We failed to reject the null hypothesis of Hardy-Weinberg equilibrium for this non-
synonymous SNP within each breed. 
  
4. Discussion  
ADGRL3, also known as LPHN3, is a member of the latrophilin subfamily of secretin G 
protein coupled receptors that is expressed in the striatum, a part of the brain important for 
motor control and reward [27]. ADGRL3 is known to play a role in glutamatergic synapse 
development [28]. Loss of function in a homolog, lphn3.1, leads to a hyperactive motor 
phenotype in developing zebrafish and in the ADGRL1 knock-out mouse [29, 30]. This study 
is the first to associate ADGRL3 polymorphism with equine disease.  
 
The only two living individuals possessing the homozygous EDM associated genotype have 
not yet exhibited signs of EDM. The two proband cases had limited access to green forage 
and were not supplemented with alpha-tocopherol, resulting in low serum concentrations. We 
know that supplementation of Vitamin E began on the farm after the initial diagnosis of EDM 
and hypothesize that these two living homozygous individuals may have had adequate levels 
of vitamin E during the early life risk period preventing them from displaying clinical signs 
or delaying the onset of EDM [13]. Further study and a larger sample size are needed to 
confirm the suspected interaction between vitamin E levels and the risk genotype.  
 
9 
 
This study demonstrates the feasibility of identifying recent recessive mutations in very small 
sample sizes using Autozygosity by Difference . However, the recessive inheritance pattern 
seen here contrasts with other studies of EDM in other breeds [1, 3, 9, 10]. EDM may be due 
to multiple breed-specific mutations preventing researchers from identifying a single causal 
mutation across multiple studies and different breeds.  
 
5. Conclusions  
The non-synonymous SNP identified in this study appears to be a genetic risk factor, working 
in conjunction with environmental factors, in the development of the EDM in the Caspian 
breed. However, observing no other homozygotes among Arabians, Miniatures, and 
Shetlands suggests that the homozygote state could also be a risk factor within those breeds. 
To validate this hypothesis, individuals diagnosed with EDM from other breeds should be 
genotyped at this SNP. This would determine if this SNP may also be a risk factor for EDM 
across all breeds or only for Caspian EDM. Further study is needed to confirm the suspected 
interaction between  
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Tables 
 
 
Table 1. Genotype & Allele Frequencies of Individuals tested for chr3:71,770,084 SNP 
 Genotype Count & Frequency Allele Frequency 
Breed Number AA AG GG A G 
Arabian 48 46 (95.8%) 2 (4.2%)  0 (0%) 0.979 0.021 
Mini1 69 61 (88.4%) 8 (11.6%) 0 (0%) 0.942 0.058 
Shetland 14 11 (78.6%) 3 (21.4%) 0 (0%) 0.893 0.107 
Caspian2 79 59 (74.7%) 18 (22.7%) 2 (2.6%) 0.861 0.139 
 
1. American Miniature Horse  
2. Includes 2 Caspian sired crossbreds, proband cases were excluded from allele 
frequency calculation  
 
 
Figure legends 
Figure 1: A) Plot of ABD score differences between cases and controls, showing a region of 
significance on ECA3. Higher ABD scores indicate SNPs are located in a region of longer 
ROH. B) shows the ABD scores for all SNPs on ECA3 with the highest ABD scoring SNPs 
circled; blue line indicates controls, red indicates cases, and green indicates the ABD score 
difference. C) Genome browser view of the region with the highest ABD score difference 
(UCSC Genome Browser, Santa Cruz, CA). ADGRL3 is the only candidate gene within the 
region. 
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